Boston Scientific Corporation
BSX Healthcare Medical Devices
Boston Scientific Corporation’s revenue for fiscal 2025 (year ended December 2025) was $20.1 billion, up 19.9% from fiscal 2024. In the quarter to June 2026, revenue grew 7.53%, EPS grew 14.8%, free cash flow grew 13.3% and total debt rose 8.95%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
Follow BSX
Boston Scientific Corporation 10-K filed Feb 17, 2026
What changed
Item 7, Management’s Discussion and Analysis, against the 10-K filed Feb 18, 2025: 16 added · 43 removed · 82 modified; 9 with only figures updated; 2 moved without change
141 more changes in this Item, word by word, in Powerpack.
Powerpack